{"id":4060,"date":"2018-05-16T21:47:33","date_gmt":"2018-05-16T21:47:33","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=4060"},"modified":"2020-12-13T18:14:09","modified_gmt":"2020-12-13T23:14:09","slug":"eiger-press-release-2","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/ko\/2018\/05\/16\/eiger-press-release-2\/","title":{"rendered":"JAMA \uc5f0\uad6c \uc774\ud6c4, PRF\uc640 Eiger BioPharmaceuticals\uac00 Lonafarnib\uc758 FDA \uc2b9\uc778\uc744 \ucd94\uc9c4\ud558\uae30 \uc704\ud574 \ud611\ub825"},"content":{"rendered":"<p>[et_pb_section fb_built=&quot;1&quot; _\ube4c\ub354_\ubc84\uc804=&quot;3.22&quot;][et_pb_row _\ube4c\ub354_\ubc84\uc804=&quot;3.25&quot; \ubc30\uacbd_\ud06c\uae30=&quot;\ucd08\uae30&quot; \ubc30\uacbd_\uc704\uce58=&quot;\uc67c\ucabd_\uc704&quot; \ubc30\uacbd_\ubc18\ubcf5=&quot;\ubc18\ubcf5&quot;][et_pb_\uc5f4 \uc720\ud615=&quot;4_4&quot; _\ube4c\ub354_\ubc84\uc804=&quot;3.25&quot; \uc0ac\uc6a9\uc790 \uc9c0\uc815_\ud328\ub529=&quot;|||&quot; \uc0ac\uc6a9\uc790 \uc9c0\uc815_\ud328\ub529__\ud638\ubc84=&quot;|||&quot;][et_pb_text _\ube4c\ub354_\ubc84\uc804=&quot;4.6.5&quot; \ubc30\uacbd_\ud06c\uae30=&quot;\ucd08\uae30&quot; \ubc30\uacbd_\uc704\uce58=&quot;\uc67c\ucabd_\uc704&quot; \ubc30\uacbd_\ubc18\ubcf5=&quot;\ubc18\ubcf5&quot; \ud638\ubc84_\ud65c\uc131\ud654=&quot;0&quot; \uc2a4\ud2f0\ud0a4_\ud65c\uc131\ud654=&quot;0&quot;]<\/p>\n<p>\ud611\ub825\uc740 \ud504\ub85c\uac8c\ub9ac\uc544 \uce58\ub8cc\uc5d0 \ub300\ud55c \uccab \ubc88\uc9f8 \uc81c\ucd9c\uc744 \uc758\ubbf8\ud569\ub2c8\ub2e4. \uc2b9\uc778\ub418\uba74 \uc5b4\ub9b0\uc774\ub294 \uc784\uc0c1 \uc2dc\ud5d8 \ub300\uc2e0 \ucc98\ubc29\uc73c\ub85c \uc57d\ubb3c\uc744 \uc0ac\uc6a9\ud560 \uc218 \uc788\uc2b5\ub2c8\ub2e4!!<\/p>\n<p>\ucd5c\uc2e0 \ubcf4\ub3c4\uc790\ub8cc\ub97c \uc5ec\uae30\uc5d0\uc11c \uc77d\uc5b4\ubcf4\uc138\uc694:<\/p>\n<ul>\n<li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/PRF-Eiger-FINAL-Press-release.pdf\">Progeria Research Foundation, Eiger BioPharmaceuticals\uc640 \ud611\ub825 \ubc0f \uacf5\uae09 \uacc4\uc57d \ubc1c\ud45c\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/04\/PRF-JAMA-Announcement_Press-Release-1.pdf\">JAMA\uc5d0 \uac8c\uc7ac\ub41c \uae00\ub85c\ubc8c \uc5f0\uad6c\uc5d0\uc11c \ub85c\ub098\ud30c\ub2d9 \uce58\ub8cc\uac00 \ud504\ub85c\uac8c\ub9ac\uc544 \uc544\ub3d9\uc758 \uc0dd\uc874 \uae30\uac04\uc744 \uc5f0\uc7a5\ud55c\ub2e4\ub294 \uc0ac\uc2e4\uc774 \ubc1d\ud600\uc84c\uc2b5\ub2c8\ub2e4.<\/a><\/li>\n<\/ul>\n<div id=\"attachment_9151\" style=\"width: 285px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-9151\" class=\"size-medium wp-image-9151\" src=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/12\/getting-drug-zoeycarly-April-2016-1-275x300.jpg\" alt=\"\" width=\"275\" height=\"300\" \/><p id=\"caption-attachment-9151\" class=\"wp-caption-text\">\uc870\uc774\uc640 \uce7c\ub9ac\ub294 \ubcf4\uc2a4\ud134\uc5d0\uc11c \uc9c4\ud589\ub41c \ucd5c\uadfc \uc784\uc0c1 \uc2dc\ud5d8\uc5d0\uc11c \ub85c\ub098\ud30c\ub2d9 \uce58\ub8cc\ub97c \ubc1b\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p><\/div>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"<p>JAMA \uc5f0\uad6c\uc5d0 \uc774\uc5b4 PRF\uc640 Eiger BioPharmaceuticals\uac00 Lonafarnib\uc5d0 \ub300\ud55c FDA \uc2b9\uc778\uc744 \ucd94\uc9c4\ud558\uae30 \uc704\ud574 \ud30c\ud2b8\ub108\uc2ed\uc744 \ub9fa\uc5c8\uc2b5\ub2c8\ub2e4. \t<\/p>","protected":false},"author":2,"featured_media":11817,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"<p>Collaboration marks the first submission for the treatment of Progeria. If approved, children may access drug by prescription instead of clinical trial!!<\/p><p>Read our latest press releases here:<\/p><ul><li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/PRF-Eiger-FINAL-Press-release.pdf\">Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals\u00a0<\/a><\/li><li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/04\/PRF-JAMA-Announcement_Press-Release-1.pdf\">Global Study Published in JAMA Finds Treatment with Lonafarnib Extends Survival in Children with Progeria<\/a><\/li><\/ul>[caption id=\"attachment_9151\" align=\"aligncenter\" width=\"275\"]<img class=\"size-medium wp-image-9151\" src=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/12\/getting-drug-zoeycarly-April-2016-1-275x300.jpg\" alt=\"\" width=\"275\" height=\"300\" \/> Zoey and Carly getting their lonafarnib treatment during their latest clinical trial visit to Boston.[\/caption]<p>\u00a0<\/p>","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[],"class_list":["post-4060","post","type-post","status-publish","format-image","has-post-thumbnail","hentry","category-news","post_format-post-format-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/ko\/2018\/05\/16\/eiger-press-release-2\/\" \/>\n<meta property=\"og:locale\" content=\"ko_KR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/ko\/2018\/05\/16\/eiger-press-release-2\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-16T21:47:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-12-13T23:14:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"225\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\ubd84\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib\",\"datePublished\":\"2018-05-16T21:47:33+00:00\",\"dateModified\":\"2020-12-13T23:14:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/\"},\"wordCount\":159,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"ko-KR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/\",\"name\":\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"datePublished\":\"2018-05-16T21:47:33+00:00\",\"dateModified\":\"2020-12-13T23:14:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#breadcrumb\"},\"inLanguage\":\"ko-KR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ko-KR\",\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"width\":300,\"height\":225},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ko-KR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ko-KR\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ko-KR\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\/\/www.progeriaresearch.org\/ko\/author\/karenb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/ko\/2018\/05\/16\/eiger-press-release-2\/","og_locale":"ko_KR","og_type":"article","og_title":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation","og_description":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib.","og_url":"https:\/\/www.progeriaresearch.org\/ko\/2018\/05\/16\/eiger-press-release-2\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2018-05-16T21:47:33+00:00","article_modified_time":"2020-12-13T23:14:09+00:00","og_image":[{"width":300,"height":225,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"1\ubd84"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib","datePublished":"2018-05-16T21:47:33+00:00","dateModified":"2020-12-13T23:14:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/"},"wordCount":159,"commentCount":0,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","articleSection":["News"],"inLanguage":"ko-KR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/","url":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/","name":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","datePublished":"2018-05-16T21:47:33+00:00","dateModified":"2020-12-13T23:14:09+00:00","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#breadcrumb"},"inLanguage":"ko-KR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/"]}]},{"@type":"ImageObject","inLanguage":"ko-KR","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","width":300,"height":225},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"\ud504\ub85c\uac8c\ub9ac\uc544 \uc5f0\uad6c \uc7ac\ub2e8","description":"\uc544\uc774\ub4e4\uc744 \uc704\ud574 \u2665 \uce58\ub8cc\ub97c \uc704\ud574","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ko-KR"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"\ud504\ub85c\uac8c\ub9ac\uc544 \uc5f0\uad6c \uc7ac\ub2e8","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"ko-KR","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"\uce74\ub80c \ubca0\ud22c\ub974\ub124\uc774","image":{"@type":"ImageObject","inLanguage":"ko-KR","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/ko\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/posts\/4060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/comments?post=4060"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/posts\/4060\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/media\/11817"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/media?parent=4060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/categories?post=4060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/tags?post=4060"}],"curies":[{"name":"\uc6cc\ub4dc\ud504\ub808\uc2a4","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}